Whanin Pharm (016580) - Total Assets
Based on the latest financial reports, Whanin Pharm (016580) holds total assets worth ₩478.89 Billion KRW (≈ $324.54 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 016580 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Whanin Pharm - Total Assets Trend (2009–2025)
This chart illustrates how Whanin Pharm's total assets have evolved over time, based on quarterly financial data. Explore 016580 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Whanin Pharm - Asset Composition Analysis
Current Asset Composition (December 2025)
Whanin Pharm's total assets of ₩478.89 Billion consist of 47.7% current assets and 52.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 13.3% |
| Accounts Receivable | ₩61.88 Billion | 12.9% |
| Inventory | ₩96.32 Billion | 20.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩9.29 Billion | 1.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Whanin Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 016580 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Whanin Pharm's current assets represent 47.7% of total assets in 2025, a decrease from 81.4% in 2009.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 26.2% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 20.1% of total assets.
Whanin Pharm Competitors by Total Assets
Key competitors of Whanin Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Whanin Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.04 | 4.75 | 7.93 |
| Quick Ratio | 2.34 | 3.04 | 6.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩171.77 Billion | ₩158.92 Billion | ₩193.23 Billion |
Whanin Pharm - Advanced Valuation Insights
This section examines the relationship between Whanin Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.41 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 12.8% |
| Total Assets | ₩478.89 Billion |
| Market Capitalization | $106.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Whanin Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Whanin Pharm's assets grew by 12.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Whanin Pharm (2009–2025)
The table below shows the annual total assets of Whanin Pharm from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩478.89 Billion ≈ $324.54 Million |
+12.76% |
| 2024-12-31 | ₩424.71 Billion ≈ $287.82 Million |
+5.85% |
| 2023-12-31 | ₩401.23 Billion ≈ $271.91 Million |
+8.62% |
| 2022-12-31 | ₩369.37 Billion ≈ $250.32 Million |
+4.58% |
| 2021-12-31 | ₩353.19 Billion ≈ $239.35 Million |
+7.17% |
| 2020-12-31 | ₩329.56 Billion ≈ $223.34 Million |
+8.09% |
| 2019-12-31 | ₩304.88 Billion ≈ $206.62 Million |
+5.98% |
| 2018-12-31 | ₩287.69 Billion ≈ $194.96 Million |
+4.68% |
| 2017-12-31 | ₩274.84 Billion ≈ $186.25 Million |
+12.90% |
| 2016-12-31 | ₩243.44 Billion ≈ $164.98 Million |
+34.18% |
| 2012-12-31 | ₩181.43 Billion ≈ $122.95 Million |
+9.22% |
| 2011-12-31 | ₩166.11 Billion ≈ $112.57 Million |
+39.65% |
| 2009-12-31 | ₩118.95 Billion ≈ $80.61 Million |
-- |
About Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, an… Read more